Catalyst Pharmaceuticals (CPRX) Operating Income (2010 - 2026)

Catalyst Pharmaceuticals has reported Operating Income for 17 years, with the latest figure at $73.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income rose 15.57% year-over-year to $73.2 million; the trailing twelve-month figure through Mar 2026 stood at $267.6 million (up 15.68% YoY), and the FY2025 full-year result was $257.8 million, up 32.11% from the prior year.
• Operating Income for Q1 2026 stood at $73.2 million, up from $61.8 million in the prior quarter.
• The five-year high for Operating Income was $73.2 million in Q1 2026, with the low at -$37.2 million in Q3 2023.
• Historically, Operating Income has averaged $42.0 million across 5 years, with a median of $46.7 million in 2023.
• Annual changes were most pronounced in 2023 — Operating Income slumped 248.15% — and 2024, when it jumped 236.9%.
• Catalyst Pharmaceuticals' Operating Income stood at $30.8 million in 2022, then surged by 35.36% to $41.7 million in 2023, then soared by 50.73% to $62.8 million in 2024, then retreated by 1.59% to $61.8 million in 2025, then grew by 18.41% to $73.2 million in 2026.
• The last three Operating Income figures came in at $73.2 million (Q1 2026), $61.8 million (Q4 2025), and $66.3 million (Q3 2025), per Business Quant data.